RIVAROXABAN

Brand name:

• Xarelto®

Pharmaceutical company:

Bayer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

PBAC Submission type:

New listing (Minor)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2020

Related medicines:

• RIVAROXABAN

Submission received for:

July 2020 PBAC meeting

Opportunity for consumer comment:

Open 29/04/2020 and close 10/06/2020 (see PBS Website)

PBAC meeting:

Held on 08/07/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

03/08/2020

Lodgement of required documentation:

14/08/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 27/08/2020

Status:

Finalised

Government processes:

Commenced on 10/09/2020

Medicine listed on the PBS:

01/12/2020 (see PBS schedule)

---